Video

Dr. Cristofanilli Discusses ALK Amplification in IBC

Massimo Cristofanilli, MD, from Fox Chase Cancer Center, discusses the investigation of small-molecule ALK inhibitors to treat patients with inflammatory breast cancer.

Massimo Cristofanilli, MD, Chair in Medical Oncology, Director of Translational Science, Cancer Genome Institute, Fox Chase Cancer Center, discusses the investigation of small-molecule anaplastic lymphoma kinase (ALK) inhibitors to treat patients with inflammatory breast cancer (IBC).

Cristofanilli notes that similar to other malignancies abnormalities in ALK seem to be a feature of IBC. As a result, several preclinical and early-stage trials have been undertaken to examine the efficacy of inhibiting ALK in IBC.

A preclinical study examining the ALK-targeted agent crizotinib showed superiority to chemotherapy for patients with IBC. Additionally, in a phase I trial the investigatory agent LDK378 was used to treat patients with tumors that were characterized by abnormalities in the ALK gene. This trial enrolled 4 patients with IBC in the dose escalation phase with plans to enroll further patients in the expansion portion of the trial, Cristofanilli adds.

Researchers are in the early phases of studying the mechanism of ALK-related oncogenicity in IBC, with the hope that it will lead to a new treatment model.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity